Carriage of penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-valent pneumococcal vaccine era.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 29 07 2018
revised: 18 01 2019
accepted: 19 01 2019
pubmed: 28 1 2019
medline: 14 6 2019
entrez: 28 1 2019
Statut: ppublish

Résumé

To determine the antibiotic susceptibility and serotype distribution of colonizing Streptococcus pneumoniae in Tanzanian children. Serial cross-sectional surveys were performed following the national introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in December 2012. A total of 775 children less than 2 years of age were recruited at primary health centres in Moshi, Tanzania between 2013 and 2015, and samples were obtained from the nasopharynx. S. pneumoniae were isolated by culture and tested for antibiotic susceptibility by disc diffusion and E-test methods; molecular testing was used to determine serotype/group. Penicillin non-susceptibility in the isolated pneumococci increased significantly from 31% (36/116) in 2013, to 47% (30/64) in 2014 and 53% (32/60) in 2015. Non-susceptibility to amoxicillin/ampicillin and ceftriaxone was low (n=8 and n=9, respectively), while 97% (236/244) of the isolates were non-susceptible to trimethoprim-sulfamethoxazole. The majority of the children (54%, n=418) had been treated with antibiotics in the past 3 months, and amoxicillin/ampicillin were overall the most commonly used antibiotics. Carriage of penicillin-non-susceptible pneumococci was more common in children with many siblings. The prevalence of PCV13 serotypes among the detected serotypes/groups decreased from 56% (40/71) in 2013 to 23% (13/56) in 2015. Penicillin non-susceptibility in S. pneumoniae colonizing Tanzanian children increased during an observation period shortly after the introduction of PCV13. Measures to ensure rational use of antibiotics and more effective systems for surveillance of antibiotic resistance and serotype distribution are needed to assure continued effective treatment of pneumococcal disease.

Identifiants

pubmed: 30685588
pii: S1201-9712(19)30046-3
doi: 10.1016/j.ijid.2019.01.035
pii:
doi:

Substances chimiques

13-valent pneumococcal vaccine 0
Anti-Bacterial Agents 0
Penicillins 0
Pneumococcal Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

156-166

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Matilda Emgård (M)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Centre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden. Electronic address: matilda.emgard@gu.se.

Sia E Msuya (SE)

Institute of Public Health, Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania; Department of Community Medicine, Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

Balthazar M Nyombi (BM)

Institute of Public Health, Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania; Department of Community Medicine, Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.

Dominic Mosha (D)

Institute of Public Health, Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.

Lucia Gonzales-Siles (L)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Rickard Nordén (R)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Shadi Geravandi (S)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Victor Mosha (V)

Institute of Public Health, Kilimanjaro Christian Medical University College (KCMUCo), Moshi, Tanzania.

Josefine Blomqvist (J)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Sofie Franzén (S)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Fredrika Sahlgren (F)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

Rune Andersson (R)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Centre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.

Susann Skovbjerg (S)

Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Centre for Antibiotic Resistance Research (CARe), University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH